On paper, things should be looking up for Japan’s pharmaceutical wholesalers. Industry expectations are mounting that the average gap between NHI and market prices will narrow further in FY2026 from the previous year’s record low of 4.8%.A shrinking gap should…
HOME > TOP STORIES
TOP STORIES
-
BUSINESS Fuji, J&J Reach Agreement on Simponi Biosimilar for 2026 Debut
November 5, 2025
-
BUSINESS Sumitomo within Striking Distance of 250-Billion-Yen Goal for 3 Key Drugs
November 4, 2025
-
BUSINESS Daiichi Sankyo’s Profit Down on HER3-DXd Delay, One-Off CMO Costs
November 4, 2025
-
BUSINESS Pfizer Resumes Supply of Smoking Cessation Pill Champix after 4 Years
October 31, 2025
-
BUSINESS Ono’s Sales Rise 7% on Overseas Growth of Qinlock, Romvimza
October 31, 2025
-
REGULATORY LDP Eyes Support for Drug Wholesalers in Upcoming Economic Package
October 31, 2025
-
REGULATORY Shionogi/Sage’s Zurzuvae Clears MHLW Panel, Label Wording on Combo Use under Review
October 31, 2025
-
REGULATORY Japan Mulls Full Overhaul of LLP Rule under FY2026 Drug Pricing Reform
October 30, 2025
-
REGULATORY Data Error Delayed Japan Review of Subcutaneous Rybrevant; Approval Still Expected This Year
October 30, 2025
-
REGULATORY Public-Private WG’s Discussion Summary Focuses on Drug Pricing, Raises MFN Risk
October 29, 2025
-
BUSINESS NEC Crafts Data Platform to Advance Personalized Cancer Vaccine Program
October 28, 2025
-
BUSINESS Shionogi Sees Flat 1H Results, Gains Domestic Support from Torii
October 28, 2025
-
BUSINESS Novo to End Sales of Victoza in Japan, Fourth GLP-1 to Exit Market
October 28, 2025
-
BUSINESS First Oral Small-Molecule GLP-1 Nears Filing; Broad Use Expected in Diabetes
October 27, 2025
-
BUSINESS Chugai Acquires Renalys Pharma, Bags IgAN Drug
October 27, 2025
-
BUSINESS Celltrion Files Biosimilar without Japanese Clinical Data, More Firms Might Follow
October 24, 2025
-
BUSINESS Earnings Season Kicks Off, Off-Year Revision Impact in Spotlight
October 24, 2025
-
BUSINESS And Pharma Group Subsidiaries Team Up for First Joint Promotion
October 23, 2025
-
REGULATORY MHLW Sets Interim Nitrosamine Limit for Atomoxetine, 5 Generic Makers Launch Fresh Recalls
October 23, 2025
-
REGULATORY Public-Private WG to Compile Industry Proposals on Drug Pricing Reforms at Next Session
October 23, 2025
ページ
Japan is set to add 16 new drugs to its NHI reimbursement price list on November 13, including a subcutaneous…
Japan will trim the NHI price of Eli Lilly Japan’s Alzheimer’s treatment Kisunla (donanemab) by 3.93% under the cost-effectiveness assessment…
Tariffs have been a defining feature of US trade policy under President Donald Trump’s second administration. Since Trump unveiled his “reciprocal” tariff policy in April 2025, the landscape has shifted repeatedly.In February 2026, the US Supreme Court invalidated tariffs imposed…
As Japan’s budget season draws near, the Ministry of Finance (MOF) has renewed its push for a full-scale “off-year” drug…
Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…